DEFA14A: Masimo Responds to Politan's Allegations Amid Proxy Contest

Masimo refutes claims by Politan Capital Management regarding shared non-public information and alleged empty voting schemes as the proxy battle intensifies.

Summary

• Masimo Corporation has issued a statement addressing allegations made by Politan Capital Management LP concerning the sharing of material non-public information and an 'empty voting' issue.
• The company denies that Mr. Kiani or any other member of management or any non-Politan members of the Board shared material non-public information with any stockholder.
• Masimo asserts that the information shared was merely a response to Politan's announcement of a second proxy contest.
• The company also denies any agreement regarding the trading or voting of Masimo stock by any third-party investor.
• Masimo claims that Politan conceived the 'empty voting' issue as a false narrative to gain control of Masimo.
• The company has filed a revised proxy statement and an amended revised proxy statement with the SEC for its 2024 Annual Meeting of Stockholders.
• Stockholders are encouraged to read the amended revised proxy statement and accompanying updated gold proxy card as they contain important information.
• Previous proxies submitted will be disregarded, and all stockholders need to resubmit their votes.
• The company, its directors, and certain executive officers may be deemed participants in the solicitation of proxies for the 2024 Annual Meeting.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the ongoing dispute and accusations between Masimo and Politan. The situation creates uncertainty and potential risks for investors.

Positives

• Masimo is actively communicating with shareholders to address concerns raised by Politan.
• The company is providing updated information through revised proxy statements.
• Masimo is defending itself against what it believes are false allegations.

Negatives

• The ongoing dispute with Politan Capital Management creates uncertainty for investors.
• The need to resubmit votes may cause confusion or inconvenience for stockholders.
• The allegations of false narratives and misinformation could damage the reputation of both Masimo and Politan.

Risks

• Uncertainties regarding future actions by Politan Capital Management could further escalate the proxy contest.
• The cost and management distraction associated with the proxy contest could negatively impact Masimo's operations.
• Failure to drive long-term value creation could lead to further challenges from activist investors.
• The outcome of the proxy contest could result in changes to the board of directors and potentially the company's strategy.

Future Outlook

The document includes forward-looking statements regarding the 2024 Annual Meeting and potential stockholder approval of the Board's nominees, but cautions that actual results could differ materially due to various risk factors.

Management Comments

• Politan continues to lie to advance a false narrative and confuse shareholders.
• Neither Mr. Kiani nor any other member of management nor any non-Politan members of the Board has ever shared material non-public information with any stockholder.
• Neither Mr. Kiani nor any other member of management nor the non-Politan members of the Board had or has any agreement with regard to the trading or voting of Masimo stock by any third-party investor.

Industry Context

Activist investors like Politan Capital Management often target companies they believe are undervalued or poorly managed, leading to proxy contests and potential changes in corporate strategy. This situation reflects a broader trend of increased shareholder activism in the healthcare technology sector.

Comparison to Industry Standards

• It's difficult to compare this situation directly to industry standards without specific details on Masimo's financial performance and governance practices.
• Proxy contests are not uncommon, but the specific allegations and counter-allegations in this case are unique to Masimo and Politan.
• Companies like Medtronic and Edwards Lifesciences also face shareholder scrutiny, but their situations may differ in terms of the specific issues and the level of engagement with activist investors.

Stakeholder Impact

• Shareholders face uncertainty due to the proxy contest and potential changes in the company's direction.
• Employees may be affected by changes in management or strategy resulting from the proxy contest.
• Customers and suppliers could be impacted if the company's focus shifts due to the influence of Politan.

Next Steps

• Stockholders need to review the Amended Revised Proxy Statement and resubmit their votes for the 2024 Annual Meeting.
• Masimo will continue to engage with stockholders to address their concerns and solicit their support for the Board's nominees.
• The outcome of the 2024 Annual Meeting will determine the composition of the Board of Directors and potentially the future direction of the company.

Key Dates

Keywords

Masimo, Politan Capital Management, Proxy Contest, Annual Meeting, Stockholders, Proxy Statement, Voting, Allegations, Board of Directors, SEC